English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

1 PG Resident, Department of Obstetrics & Gynecology, Govt medical College Kota, Rajasthan, India 2 Assistant Professor, Department of Obstetrics & Gynecology, Govt medical College Kota, Rajasthan, India 3 Professor, Department of Obstetrics & Gynecology, Govt Medical College Kota, Rajasthan, India 4 Assistant Professor, Department of Medicine, Govt Medical College Kota, Rajasthan, India Corresponding Author Dr Mamta Sharma Professor, Department of Department of Obstetrics & Gynecology, J K Lon Hospital, Govt Medical College Kota Rajasthan India Address – Type III/10, Medical College Campus, Govt Medical College Kota Rajasthan Pin Code 324005 Email: patidar.badri@gmail.com, Mobile num. 9414570937 Abstract Background: Anemia is one of the most commonly encountered medical disorders in pregnancy & Iron deficiency is the leading cause of anemia in pregnancy. Aim of the study was to assess the efficacy of Iron Sucrose and Iron Sorbitol Citric Acid & to assess the safety and tolerability of these drugs in pregnant women with moderate anemia. Methods: In this study, 100 antenatal cases of gestational age 14-32 weeks with hemoglobin 7-9 gm/dl were randomly divided into two groups of 50 each, which received a fixed dose of IV Iron Sucrose (Group A) & IM Iron Sorbitol Citric Acid therapy (Group B). The efficacy of the therapy was assessed by laboratory parameters such as hemoglobin, hematocrit, MCV, MCH, MCHC and serum ferritin level after 14 and 28 days. To assess the safety, adverse drug reactions with both the therapies were recorded. Results: Pretreatment hemoglobin was 7.6±0.35 gm/dl & 7.6±0.31 gm/dl in Group A & B respectively. Hemoglobin concentration increased significantly (P<0.001), increase in Hb after 4 weeks of starting therapy was 1.2 gm/dl & 0.5 gm/dl in Group A & Group B respectively. Rise in other parameters (MCV, Ferritin etc) although were minimal but more in IV Group & statistically significant (p<0.05). Adverse events were more common with Iron Sorbitol Citric Acid therapy. Conclusion: Intravenous therapy appears to be safer, faster, effective & more convenient than Intramuscular therapy in treatment of Iron deficiency anemia during pregnancy.

Study for Comparison of Iron Sucrose & Iron Sorbitol Citrate in Fixed Doses in Iron Deficiency Anemia during Pregnancy in a Tertiary Care Center